Their proprietary T-cell Antigen Coupler (TAC) technology recruits the entire natural T-cell receptor and functions independently of the Major Histocompatibility Complex (MHC), allowing for the development of safer and more effective therapies for a broader range of patients with solid or liquid malignancies and other diseases. The company was co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co. and is made up of a team of experienced professionals from various industries and academia who are passionate about pushing scientific limits, helping patients, and promoting employee wellness. Triumvira is an emergent US company with operations in the United States and Canada that offers innovative and flexible career opportunities.